Beyond Cosmax & Kolmar: 7 Korean ODMs Indie Founders Should Know

By the ALTA MEET editorial team | K-beauty ODM consulting (NYC × Seoul)

Most US indie K-beauty founders start their Korean manufacturing research by typing "Korean ODM" into Google. They land on the same two names: Cosmax and Kolmar Korea. Both are real industry leaders. Both also turn down most first-time founders, either at the brief stage or after a discovery call where the founder learns the project doesn't clear the internal revenue threshold.

The Korean cosmetics ODM market is much larger than those two companies. Cosmax holds an estimated 14 to 18 percent of Korean ODM market share, and Kolmar Korea holds 12 to 15 percent. Together, that's roughly a third of the market. The other two-thirds is split across hundreds of mid-tier and specialist contract manufacturers, and that is where most indie K-beauty production actually happens. This guide profiles the seven Korean ODMs that come up most often in our 2026 sourcing work for early-stage US brands, with the client-tier patterns, capability profiles, and indie-accessibility realities our team uses when matching a founder to a partner.

The Korean ODM Market in Numbers (2026)

Korea Biomedical Review's Q4 2025 reporting put Kolmar Korea at 2.72 trillion KRW in 2025 annual revenue and Cosmax at 2.39 trillion KRW, with both companies entering the "2 trillion won club" for the first time. Cosmecca Korea, the third major player, reported a trailing 12-month revenue of approximately $450 million as of late 2025 per PitchBook. After those top three, revenue concentration drops quickly: the rest of the industry is fragmented across a long tail of mid-sized and specialist factories, most of them privately held.

Two market forces are reshaping this hierarchy in 2026. First, K-beauty exports continue to expand in the US and ASEAN markets, and that capacity demand is pushing top-3 ODMs toward larger client books with higher minimum brand-revenue criteria. Second, US-side OTC drug demand (especially Korean-style sunscreen) is concentrating in the ODMs with FDA-registered facilities, including subsidiary plants based in the US. The practical result for indie founders: the top three ODMs are getting busier and pickier, and the mid-tier is increasingly where indie K-beauty work lands.

A useful mental model: the top three (Cosmax, Kolmar, Cosmecca) handle the bulk of large-brand contract manufacturing. The next tier of about 8 to 15 ODMs handles most of the indie K-beauty work that has actual MOQ flexibility. Below that sits a fast-growing layer of small-batch private label houses (often 500 to 1,000 unit MOQs) that are technically OEMs more than full ODMs.

Why Indie Founders Research Beyond the Top Two

Cosmax and Kolmar are dominant for genuine reasons. Both have global R&D scale, regulatory infrastructure that makes US export simpler, and decades of formulation libraries. The friction for first-time US founders is usually one of four things.

MOQ thresholds: Cosmax and Kolmar typically quote starting MOQs of 5,000 to 10,000 units per SKU for skincare, often higher for color cosmetics, and most US indie founders are launching at 1,000 to 3,000 units. The math doesn't fit.

Minimum brand-revenue requirements: both top-tier ODMs commonly screen for projected first-year revenue (we've seen $5M-plus mentioned by intake teams, though specifics vary by category and account manager). An indie launching a first SKU rarely clears that bar.

R&D queue priority: top-tier ODM development teams are usually committed to existing mega-brand clients (Innisfree, Laneige, MISSHA, plus global accounts). New, small accounts wait, and the timeline founders quoted in the discovery call can stretch substantially in practice.

Communication tier: top-tier ODMs often assign smaller accounts to junior account managers whose English fluency and decision-making authority don't match what a first-time founder needs.

None of those are reasons not to consider Cosmax or Kolmar. They are reasons indie founders end up calling our team to ask which other ODMs might fit. The B2B intel queries that have started appearing in Google Search Console over the past 60 days ("kolmar north america odm major customer 2026," for example, plus several similar variants surfacing in ChatGPT-grounded searches) are evidence that founders are already trying to do this homework themselves. It's worth doing the research carefully because the relationship usually lasts through several production cycles and is hard to unwind.

The 7 Other Korean ODMs You Should Know

The seven below are not the only mid-tier Korean ODMs; the country has 200 to 300 registered cosmetics contract manufacturers per the Korea Cosmetic Association membership lists. These are the seven that we see surface most often in our indie K-beauty engagements, and each represents a different point on the cost / accessibility / specialization axis.

1. Cosmecca Korea

Founded in 1999 and headquartered in Eumseong, Chungcheongbuk-do (with R&D in Pangyo, Seongnam), Cosmecca is the third-largest Korean cosmetics ODM by revenue. The company built early reputation in BB cream and tone-up cream formulation, and now spans skincare, sheet masks, sun care, and color. Its domestic and international client list reportedly includes Amorepacific, MISSHA, TonyMoly, and Etude House (per multiple industry directories), and the company says it serves approximately 1,200 brand clients across local and overseas accounts.

For US indie founders, Cosmecca has one structural advantage worth knowing. In 2018, Cosmecca acquired a controlling stake in Englewood Lab, a New Jersey contract manufacturer (per Beauty Matter and WWD reporting), which gave Cosmecca an FDA-registered US production footprint. That changes the regulatory math for products that need to be made or finished domestically.

MOQ practically observed: 3,000 to 5,000 units per SKU for skincare; lower if the brief uses an existing Cosmecca base formula. Brand-revenue gate: lower than Cosmax / Kolmar, but they will ask about the founder's distribution plan before quoting.

2. COSON

COSON has had a more turbulent decade than Cosmecca but is back on indie radars in 2026. The company gained recognition manufacturing the YG Entertainment-backed Moonshot brand and has a notable US partnership history (per published industry coverage and the company's own materials), including Tarte at one point, plus GD11 and VILLAGE 11 FACTORY among Korean indie names. Post-COVID, COSON took restructuring investment from Yuhan-Yang Co. and the company has been rebuilding its account book.

COSON's accessibility for US indies right now is genuinely better than its top-tier peers, because the company is actively rebuilding its client pipeline. The trade-off is that some R&D depth that existed pre-2020 has thinned, and the partnership is best for founders bringing a clearer brief rather than relying on the ODM to drive innovation.

3. HANACOS

Located in Hoengseong-gun, Gangwon-do, HANACOS Co., Ltd is a mid-tier ODM with 100-plus employees and reported sales in the range of 11.5 billion KRW (per Kompass and the company's own published materials). HANACOS supplies skincare and color cosmetics to brands including Missha, TonyMoly, and Amorepacific (per industry directories), and the company has been pushing hard on export-led growth, which means the inquiry funnel is open to US indies in a way that the top-tier ODMs are not.

HANACOS is one of the more reliable "second SKU" partners we see. Founders who launched their first product with a low-MOQ small-batch OEM often graduate to a mid-tier like HANACOS for their second or third product, where reorder economics and quality consistency start to matter more.

4. Cosvision

Cosvision is the cautionary tale in this list. Founded in 2008 in Daejeon, the company was acquired by AmorePacific Group in 2011 (per published industry coverage and Crescent Seoul reporting). It functions today primarily as AmorePacific's captive ODM, producing for Etude House, Innisfree, Mamonde, and Aritaum.

Cosvision's facility quality and R&D depth are real. The catch is that it rarely accepts external indie work, especially from non-Korean founders. We mention it here because founders who hear "Cosvision" mentioned by a Korean trading-house intermediary should understand the dynamic: the trading house can probably get a Cosvision base formula commercially licensed, but it is functionally captive, and lead times will track AmorePacific's internal priorities rather than yours.

5. iM1NE

iM1NE has been a sheet mask and hydrogel specialist since 2006. The company says it has 24 registered independent technology patents, 130 original materials, and that it has partnered with more than 100 brands across 40 countries. Several US indies we've worked with have used iM1NE for hydrogel masks and patches, including spot patches and sheet masks built around the company's own technology base.

For founders considering sheet masks as a category extension or first SKU, iM1NE is usually a faster path than going to a generalist ODM, because the formulation library and substrate sourcing are already in place. The trade-off: if you also want a serum, ampoule, or cream to launch alongside the mask, you'll typically need a second partner for the bottled SKUs.

6. Englewood Lab (Cosmecca's NJ subsidiary)

Strictly speaking, Englewood Lab is a US contract manufacturer, not a Korean ODM. We include it on this list because it's a Cosmecca-owned facility (since 2018) and a frequent recommendation for any Korean-developed formula that needs FDA OTC drug capability or US-side compliance simplification.

Per Englewood Lab's published company materials, the company has plants in Englewood and Totowa, New Jersey, with capacity for approximately 87 million products per year, and the company secured FDA OTC drug manufacturing authorization in 2019. For founders whose first SKU is a Korean-style sunscreen (an OTC drug in the US, regardless of where the SPF testing was done), or who want a US "Made in USA" supply chain footprint while keeping Korean R&D, Englewood Lab is one of the more practical options because the parent-subsidiary relationship lets the formulation work happen in Korea while final manufacture happens in NJ.

7. Crescent Seoul, Mayk Factory, and the Indie-Tier OEM Layer

The seventh entry is really a category rather than a single name. Over the past three to four years, a layer of indie-friendly OEMs has formed in Korea that accept MOQs of 500 to 1,500 units per SKU, with development cycles of 6 to 8 weeks rather than the 12 to 16 weeks typical at top-tier ODMs. Companies in this segment that come up most often in our intake conversations include Crescent Seoul, Mayk Factory, k-beautyodm, and a handful of smaller private-label houses oriented toward US Amazon-first or DTC-first founders.

The trade-off at this tier is straightforward: you typically work from an ODM's existing formula library (true private label) rather than developing a custom formulation from a brief, the brand-side regulatory and stability lift falls more on you, and the per-unit cost at 500 to 1,500 units will not be competitive with what a 5,000-unit batch at Cosmecca would cost on a per-unit basis. What you get in exchange is a launch you can actually finance.

I'm Liz, I run altameet from Manhattan, NYC. We spend most of our week matching US indie founders to the right Korean ODM partner across this list and a few others, and the conversation almost always starts with the founder's first-year volume math, not the brand vision. If you want a quick gut-check on which tier of Korean ODM fits your stage, grab 15 minutes free with Liz.

How These ODMs Compare on Indie-Founder Trade-Offs

The four levers that matter most for an indie K-beauty founder choosing a Korean ODM are: realistic MOQ, brand-revenue gating, lead time on a net-new custom formula, and US-side regulatory support. The table below is based on what our team observes across 2026 engagements; published company materials sometimes show more aggressive numbers than what an indie founder will actually be quoted.

ODMTypical indie MOQBrand-revenue gatingCustom-formula lead timeUS-side regulatory help Cosmax5,000 to 10,000+High (often $5M+ projected)12 to 20 weeksYes (US facility + RP support) Kolmar Korea5,000 to 10,000+High12 to 18 weeksYes (US facility via Kolmar NA) Cosmecca3,000 to 5,000Moderate10 to 16 weeksYes (via Englewood Lab) COSON3,000 to 5,000Lower (actively rebuilding)10 to 14 weeksPartial HANACOS2,000 to 5,000Lower (export-oriented)10 to 14 weeksIndirect (third-party RP) CosvisionN/A for indiesEffectively closedN/AN/A iM1NE1,000 to 3,000 (mask/hydrogel only)Lower6 to 12 weeksPartial Englewood Lab (US)3,000 to 10,000 (Cosmecca-linked)Moderate12 to 16 weeks (with Cosmecca R&D)Yes (FDA-registered US plant) Indie-tier OEMs (Crescent Seoul, Mayk, etc.)500 to 1,500Minimal6 to 8 weeks (private label)Indirect (founder handles)

Two notes on this table. First, MOQ ranges assume a single SKU per quote; bundling 2 to 3 SKUs into one PO usually moves the per-SKU MOQ floor down. Second, "lead time" is from approved brief to first production batch ready to ship; it does not include the brand-side time to finalize packaging, run challenge testing on the final fill, or wait through FDA / MoCRA registration if applicable.

A 5-Question Filter for Choosing

Most ODM mismatches we see come from founders skipping these five questions early. We use them in our intake calls before recommending which ODMs to brief.

First, what is your realistic 12-month unit volume per SKU? Multiply your distribution plan by a 0.5 to 0.7 sell-through factor for first year, because almost no first-year indie hits 100 percent sell-through. If the resulting per-SKU 12-month volume is under 3,000 units, the top-3 ODMs aren't the right starting place. If it's over 10,000 units per SKU on launch, the indie-tier OEMs will leave per-unit margin on the table.

Second, is this SKU going to be regulated as a cosmetic or an OTC drug in the US? Sunscreens and most acne products are OTC drugs in the US and need FDA-registered manufacturing for the final fill. If yes, narrow toward Cosmecca + Englewood Lab, Kolmar Korea + Kolmar NA, or Cosmax + Cosmax USA.

Third, do you need a custom formula or will an existing base work? Custom formula development is what justifies a 10 to 20 week lead time at a top-tier ODM. If you're effectively launching with an existing private-label base plus your brand story, the indie-tier OEMs are usually the rational choice for first SKU.

Fourth, does your category fit a specialist? Sheet masks and hydrogels at iM1NE will almost always outperform a generalist ODM's first attempt. Color cosmetics have a similar specialist layer (Italcosmetici, Kolmar's color division, plus several pigment-focused Korean factories) that we don't cover in detail here.

Fifth, who will own the regulatory file? MoCRA registration, adverse-event reporting, stability documentation, and the US Responsible Person designation all have to live somewhere. The top-3 ODMs and Englewood Lab can do most of this for you; the indie-tier OEMs typically expect the brand (often via a third-party RP service) to handle it.

What Goes Wrong (And How to Spot It Early)

The most common failure modes we see across the seven ODMs above fall into four buckets.

Subsidiary lock-in. If you sign with an ODM whose parent group also owns the trading house or the regulatory consultant that introduced you, expect those relationships to be tightly coupled, and expect the cost stack to reflect that. Cosvision is the textbook case (captive to AmorePacific), but mid-tier ODMs sometimes have similar entanglements with Korean trading houses. Always ask directly: "Are you owned by, or do you have a sales agreement with, [introducing party]?"

Capacity reallocation mid-cycle. Top-tier ODMs sometimes shift production capacity toward a mega-brand client mid-PO if that client places a rush. Indie POs are technically protected by the contract, but practical timeline slippage of 2 to 4 weeks is common. The way to spot this early: ask in the discovery call about their existing client mix at the production line that will run your SKU. If 80-plus percent of that line's calendar is committed to one or two large brands, your PO will be the first reshuffled.

Communication tier mismatch. The English fluency of your assigned account manager is a leading indicator of execution quality. We've seen first-time founders sign with top-3 ODMs based on the brand recognition, then get assigned a junior account manager whose English is functional but not commercially fluent. Specifically test this in the second discovery call by asking for the account manager's authority on three concrete decisions: filling tolerance, mid-PO formula tweak, and emergency stop policy. The clearer the answer, the higher the tier of attention you're actually getting.

US OTC drug compliance for sunscreen. If your SKU is a sunscreen, the question "will this be FDA-compliant?" is more complicated than "can this be made in Korea?" Korean sunscreens use a broader UV-filter palette than the FDA monograph permits (the FDA OTC sunscreen monograph allows 16 active sunscreen ingredients in the US, while KFDA permits roughly 30). An ODM can manufacture a Korean-spec sunscreen formula and you can sell it in Korea or EU but cannot legally market it in the US as a sunscreen. The ODM may not flag this proactively. Founders sometimes find out post-PO. Ask explicitly: "Is every active UV filter in this formula on the FDA OTC sunscreen monograph list?"

FAQ

Are Cosmecca, COSON, and HANACOS owned by the same parent group as Cosmax or Kolmar? No. Cosmecca, COSON, and HANACOS are independent companies as of 2026. Cosmecca is publicly listed on the Korea Exchange. Cosvision, by contrast, was acquired by AmorePacific Group in 2011 and operates as a captive subsidiary. The distinction matters because pricing transparency and indie-founder access patterns are very different at independent ODMs versus captive ones.

Can a US indie founder directly contact these Korean ODMs without going through a trading house? Yes, technically. Each of the seven ODMs above has an overseas inquiry channel or English-language sales contact, and you can email cold. The catch is the response and quote quality often varies significantly by who's introducing you. A direct cold inquiry from a first-time founder will often go to a generic intake queue. An introduction through a known intermediary (consulting firm, trading house, or existing client) tends to get routed to a senior account manager. Indie founders typically get the best result by having one or two direct conversations first to test fit, then engaging an intermediary for the formal commercial conversation.

How much does it cost to get an indie sample run from one of these mid-tier ODMs? Sample runs for confirmation production at Cosmecca, COSON, and HANACOS in our 2026 experience range from about $1,200 to $4,500 per SKU for skincare formulas, depending on whether you're modifying an existing base or developing net-new. iM1NE sample sheet mask runs tend to be lower ($800 to $2,500) because the substrate and serum architecture are already in place. Sample fee is typically credited against first PO at most of these ODMs but not all; confirm in writing.

Will any of these ODMs sign an NDA before the first call? Most will, but the NDA is usually their template, not yours. Cosmecca and the top-three ODMs have mutual NDAs that are reasonable to sign as written. Smaller ODMs sometimes have one-way NDAs favoring them. For founders launching a genuinely novel formulation concept, having your own NDA reviewed by US counsel before the first detailed conversation is worth the cost (typically $400 to $900 for a one-off mutual NDA review).

What's the difference between an "ODM" and an "OEM" in the Korean cosmetics industry? ODM (Original Design Manufacturer) means the factory develops the formula and the brand puts its name on it; OEM (Original Equipment Manufacturer) means the brand provides the formula and the factory makes it. Most Korean cosmetics ODMs do both. Indie-tier private-label houses (Crescent Seoul, Mayk Factory, others) are more OEM-leaning in practice because the formula library is pre-set; founders take an existing base and customize fragrance, color, and packaging rather than developing net-new chemistry.How long has Cosmecca been Cosmax's competitor for the third spot in the Korean ODM rankings? Cosmecca has been the consistent third-place player by revenue since the late 2010s. As of late 2025, Cosmecca's trailing 12-month revenue was approximately $450M per PitchBook, well behind Cosmax and Kolmar's combined 5+ trillion KRW but ahead of the next tier of ODMs. The gap between #3 and #4 has actually widened in the past two years because Cosmecca's Englewood Lab subsidiary has captured a meaningful share of US-bound OTC and skincare contract work.

If I'm launching a sheet mask and a serum at the same time, do I really need two different ODMs? Often yes, if you want each SKU to be category-best. iM1NE's substrate and serum-soak technology for masks isn't easily replicated at a generalist ODM, and most generalist ODMs' serum bases for bottled SKUs outperform iM1NE's bottled-format options. Founders launching with a 2-SKU starting set sometimes consolidate at a mid-tier ODM (Cosmecca or HANACOS) to keep relationship overhead lower, accepting that the mask will be merely good rather than category-leading.

Key Takeaways

Cosmax and Kolmar Korea hold roughly a third of the Korean cosmetics ODM market between them in 2025-2026 by revenue. The remaining two-thirds is split across a mid-tier of about 15 to 20 named ODMs and a long tail of specialist factories.

For US indie founders, the right Korean ODM partner is rarely the largest one. It's the one whose MOQ tier, brand-revenue gating, and communication tier match your stage. Cosmecca is often the right "graduate from indie OEM" mid-tier choice, especially for founders who need US-side OTC drug capability via Englewood Lab. COSON and HANACOS are accessible mid-tier alternatives. Cosvision is functionally closed to non-AmorePacific work. iM1NE is the right specialist for mask and hydrogel-based first SKUs.

Before the first introductory call with any Korean ODM, indie founders should be able to answer five questions: realistic 12-month per-SKU volume, cosmetic vs OTC drug classification in the US, custom vs existing base formula, category specialist vs generalist need, and who owns the regulatory file. Mismatches at the briefing stage are expensive to correct in production. Mismatches at the production stage are more expensive again.

Working With ALTA MEET

We're a Manhattan-based K-beauty manufacturing consultancy that matches US indie founders to Korean ODM partners across the full range above (and a few specialty factories that don't make this list because they're not publicly searchable). Most of our work is on first or second SKU, post-brief, pre-PO. Book a free 15-min K-Beauty manufacturing gut-check with Liz and we'll work through your specific category, MOQ, and US regulatory question.

For founders who'd rather read first, our companion pieces on this cluster include Cosmax vs Kolmar for indie K-beauty founders, Korean ODM direct vs trading house vs US beauty broker, Korean ODM MOQ tier $/unit benchmarks, and how to negotiate a Korean ODM quote line by line.

Reviewed for accuracy by ALTA MEET's formulation consulting team. Revenue figures and market-share estimates draw from Korea Biomedical Review (2025-2026), KED Global (2025), Capstone Partners M&A Beauty Coverage Report (July 2025), PitchBook (Cosmecca Korea profile, 2025), and company-published materials from Cosmecca, COSON, HANACOS, iM1NE, Englewood Lab (via Cosmecca Korea). MOQ, lead-time, and brand-revenue gating ranges reflect what our 2026 partner-quotation work has observed across actual quotes; published company materials sometimes differ. Englewood Lab acquisition details from Beauty Matter and WWD reporting (2018). Cosvision-AmorePacific relationship per Crescent Seoul published reporting. FDA OTC sunscreen monograph filter count per FDA Final Order (2019) on OTC sunscreen drug products.